Taro Pharmaceutical Industries Ltd, the US subsidiary of Sun Pharmaceuticals Industries Ltd , has received tentative approval from the US Food and Drug Administration for diclofenac sodium topical solution of 2 per cent strength. Diclofenac sodium is indicated for mild to moderate pain, or signs and symptoms of osteoarthritis or rheumatoid arthritis. Sun Pharma shares edged down 1 per cent at ₹662.3 on the BSE.
Sun Pharmaceuticals Industries Ltd
Published on
February 8, 2017 15:52
Tags